Larazotide (AT-1001)
Zonulin antagonist
Short synthetic zonulin-antagonist peptide studied for effects on intestinal tight junctions and paracellular permeability in gut-barrier research.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Zonulin antagonist
- Category
- Immune & Inflammation
- Type
- Single compound
- Development and regulatory status
- Investigational; phase 3 trial discontinued; not approved
What researchers study
Larazotide (AT-1001) is a short synthetic peptide that acts as a zonulin antagonist. It is proposed to limit tight-junction opening between intestinal cells and so reduce paracellular permeability.
Research areas
- Intestinal tight-junction regulation assays
- Gut permeability in cell monolayer models
- Celiac disease mucosal-barrier research
- Gluten-challenge clinical immunology studies
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
Phase 3 CedLara trial (525 planned patients) was stopped after an interim analysis found the sample size needed to show a difference was too large
- phase 2 trial
An earlier phase 2 study of 342 patients reported significantly reduced celiac symptoms in one treatment arm
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
